Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: Case series and review of literature

Journal of Chemotherapy

Volumn 23, Issue 1, 2011, Pages 17-23

  Masamoto, Y ^a   Nannya, Y ^a   Kurokawa, M ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Acute leukemia; Invasive aspergillosis; Secondary prophylaxis; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; IDARUBICIN; ITRACONAZOLE; METHOTREXATE; MICAFUNGIN; MITOXANTRONE; VORICONAZOLE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG MYCOSIS; NONHUMAN; PULMONARY INVASIVE FUNGAL DISEASE; PULMONARY INVASVIE FUNGAL DISEASE; RELAPSE; REVIEW; SECONDARY PREVENTION; TREATMENT OUTCOME; VISUAL DISORDER; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; LEUKEMIA; MALE; MICROBIOLOGY; MIDDLE AGED; NEUTROPENIA;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; NEUTROPENIA; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 80051776285     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.1.17     Document Type: Review

References (46)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26(4):781-803 quiz 804-5.
2. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118(7):495-503.
3. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28(2):331-340.
4. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Hueb-ner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23-32.
5. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis. 1998;26(5): 1098-1103.
6. Robertson MJ, Larson RA. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med. 1988;84(2):233-239.
7. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F. Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group. Bone Marrow Transplant. 1995;16(2):323-324.
8. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006;42(11):1584-1591.
9. Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med. 1988;85(2):203-206.
10. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albós A. Risk of reactivation of a recent invasive fungal infection in patients with hematolog- ical malignancies undergoing further intensive chemo-radiotherapy. A sin- gle-center experience and review of the literature. Haematologica. 1997;82(3):297-304.
11. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hematopoietic stem cell trans- plantation: 10-year experience at a single transplant center. Biol Blood Mar- row Transplant. 2004;10(7):494-503.
12. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-637.
13. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.
14. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563-571.
15. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 2004;33(9):943-948.
16. AUinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoi- etic stem cell recipients. J Antimicrob Chemother. 2008;61(3):734-742.
17. Comely OA, Bohme A, Reichert D, Reuter S, Maschmeyer G, Maertens J et al. Risk factors for breakthrough invasive fungal infection dur- ing secondary prophylaxis. J Antimicrob Chemother. 2008;61(4):939-946.
18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Ca- landra T et al. Revised definitions of invasive fungal disease from the Euro- pean Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
19. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-751.
20. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100(3):345-351.
21. Viollier AF, Peterson DE, De Jongh CA, Newman KA, Gray WC, Su- therland JC et al. Aspergillus sinusitis in cancer patients. Cancer. 1986;58(2):366-371.
22. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feld-man AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545-1552.
23. Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents. 2009;34(5):446-450.
24. Stute N, Kratochwille A, Zabelina T, Fehse N, Hassenpflug W, Panse J et al. Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell transplantation in patients with prior systemic or invasive fungal infections. Bone Marrow Transplant. 2004;33(SUPPL 1):735.
25. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108(9):2928-2936.
26. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L et al. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007;48(9): 1799-1805.
27. Aki ZS, Sucak GT, Yegin ZA, Guzel O, Erbas G, Senol E. Hematopoietic stem cell transplantation in patients with active fungal infection: not a contraindication for transplantation. Transplant Proc. 2008;40(5):1579-1585.
28. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95 (10): 1762-1768.
29. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O et al. Imaging findings in acute invasive pulmonary aspergillosis: clin- ical significance of the halo sign. Clin Infect Dis. 2007;44(3): 373-379.
30. Zhang P, Song A, Wang Z, Feng S, Qiu L, Han M. Hematopoietic SCT in patients with a history of invasive fungal infection. Bone Marrow Transplant. 2009;43(7):533-537.
31. Tsitsikas DA, Morin A, Murtagh B, Athom G, Suaris T, Ellis S et al. Significant reduction in the diagnosis of possible and probable invasive fungal infection by applying the revised EORTC defi nitions of invasive fungal disease. Bone Marrow Transplant. 2009;43(SUPPL 1):46.
32. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J In- fect Dis. 2004;190(3):641-649.
33. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762-1769.
34. Motohashi K, Ito S, Hagihara M, Sakai R, Tanaka M, Kawano T et al. Allogeneic hematopoietic stem cell transplantation after surgical resection of pulmonary aspergillosis in 5 patients with acute leukemia. Rinsho Ket- sueki. 2009;50(5):430-434.
35. Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361-370.
36. Uriz J, de Andoin NG, Calvo C, Landa J, Onate E, Nogues A et al. Secondary prophylaxis with voriconazole in a leukemic patient with pulmonary aspergillosis. Pediatr Infect Dis J. 2007;26(10):971-972.
37. Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marenco P et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant. 2007;39(10):631-635.
38. Grigull L, Beilken A, Schmid H, Kirschner P, Sykora KW, Linderkamp C et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14(7):783-786.
39. Dinser R, Grgic A, Kim YJ, Pfreundschuh M, Schubert J. Successful treatment of disseminated aspergillosis with the combination of voricona- zole, caspofungin, granulocyte transfusions, and surgery followed by allo- geneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft. Eur J Haematol. 2005;74(5):438-441.
40. Vaidya SJ, Ortin M, López-Duarte M, Sirohi B, Powles R, Treleaven J et al. Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma. 2005;46(8):1143-1150.
41. Lassaletta A, Perez A, Diaz MA, Sevilla J, Gonzalez-Vicent M, Madero L. Successful treatment of invasive aspergillosis with oral voriconazole following intravenous liposomal amphotericin in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2004;26(2):117-119.
42. Chow E, Moore T, Nielsen K. Case report: Invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation. Pediatr Infect Dis J. 2003;22(12):1109-1110.
43. Mattei D, Mordini N, Lo Nigra C, Ghirardo D, Ferrua MT, Osenda M et al. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant. 2002;30(12):967-970.
44. Xun CQ, McSweeney PA, Boeckh M, Storb RF, Broudy VC, Thompson JA. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. Blood. 1999;94(9):3273-3276.
45. de Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo L, Milone G et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant. 2007;40(3):245-249.
46. Kriiger WH, Riissmann B, de Wit M, Kroger N, Renges H, Sobottka I et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol. 2005;113(2):104-108.